MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in ...

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

BioNTech SE is methodically advancing its transition from a COVID-19 vaccine specialist to a fully-fledged oncology company, achieving significant regulatory and operational milestones in early 2026.

BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA’s emergency use authorization, is now using mRNA to tackle another disease: malaria. The ...

BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares ...

We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ ...

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed ...

Moderna has filed a lawsuit against Pfizer and its German partner BioNTech for allegedly copying their COVID-19 vaccine. On Friday, Moderna issued a news release accusing Pfizer of infringing several ...

For former CureVac shareholders who participated in the public exchange offer, their holdings have been converted into BioNTech American Depositary Shares (ADS) according to the agreed terms. With ...